Zeev Bronfeld - Sep 7, 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: Director
Signature: /s/ Eyal Rubin, POA
Stock symbol: PLX
Transactions as of: Sep 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/9/2022, 05:01 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLX	Stock Options (Right to Buy)	Award	$0	+100K		$0.00	100K	Sep 7, 2022	Common Stock	100K	$1.03	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant.
F2	Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030.

Content

The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant.

Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030.